221 related articles for article (PubMed ID: 32386431)
1. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.
Caroppo F; Biolo G; Belloni Fortina A
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e368. PubMed ID: 32386431
[No Abstract] [Full Text] [Related]
2. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.
Ferrucci S; Romagnuolo M; Angileri L; Berti E; Tavecchio S
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e303-e304. PubMed ID: 32330323
[No Abstract] [Full Text] [Related]
3. Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.
Kearns DG; Uppal S; Chat VS; Wu JJ
J Am Acad Dermatol; 2020 Sep; 83(3):e251-e252. PubMed ID: 32534081
[No Abstract] [Full Text] [Related]
4. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.
Rossi M; Rovati C; Arisi M; Soglia S; Calzavara-Pinton P
Dermatol Ther; 2020 Jul; 33(4):e13765. PubMed ID: 32500660
[No Abstract] [Full Text] [Related]
5. Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient.
Benhadou F; Del Marmol V
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e363-e364. PubMed ID: 32379925
[No Abstract] [Full Text] [Related]
6. 'Toxic erythema' and eosinophilia associated with tocilizumab therapy in a COVID-19 patient.
Sernicola A; Carnicelli G; Di Fraia M; Chello C; Furlan C; Muharremi R; Paolino G; Grieco T
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e368-e370. PubMed ID: 32386438
[No Abstract] [Full Text] [Related]
7. Two cases of skin manifestations prior to the onset of COVID-19 respiratory symptoms.
Altayeb A; Cordaro A; Caesar J; Vyas J; Ingram J
Int J Dermatol; 2020 Dec; 59(12):1541-1542. PubMed ID: 33084036
[No Abstract] [Full Text] [Related]
8. Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.
Georgakopoulos JR; Yeung J
J Cutan Med Surg; 2020; 24(4):422-423. PubMed ID: 32434413
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2 infection presenting as a febrile rash.
Amatore F; Macagno N; Mailhe M; Demarez B; Gaudy-Marqueste C; Grob JJ; Raoult D; Brouqui P; Richard MA
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e304-e306. PubMed ID: 32330336
[No Abstract] [Full Text] [Related]
10. Seborrheic dermatitis in COVID-19: a case report.
Alpalhão M; Gaibino N; Filipe P
Int J Dermatol; 2020 Dec; 59(12):1543-1544. PubMed ID: 33095515
[No Abstract] [Full Text] [Related]
11. Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer.
Shah MA; Mayer S; Emlen F; Sholle E; Christos P; Cushing M; Hidalgo M
JAMA Netw Open; 2020 Sep; 3(9):e2023121. PubMed ID: 32990737
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis.
Vischini G; D'Alonzo S; Grandaliano G; D'Ascenzo FM
Kidney Int; 2020 Jul; 98(1):237-238. PubMed ID: 32413379
[No Abstract] [Full Text] [Related]
13. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection.
van Damme C; Berlingin E; Saussez S; Accaputo O
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e300-e301. PubMed ID: 32329915
[No Abstract] [Full Text] [Related]
14. Minor aphthae associated with SARS-CoV-2 infection.
Dominguez-Santas M; Diaz-Guimaraens B; Fernandez-Nieto D; Jimenez-Cauhe J; Ortega-Quijano D; Suarez-Valle A
Int J Dermatol; 2020 Aug; 59(8):1022-1023. PubMed ID: 32557570
[No Abstract] [Full Text] [Related]
15. Dupilumab and COVID-19: What should we expect?
Patruno C; Stingeni L; Fabbrocini G; Hansel K; Napolitano M
Dermatol Ther; 2020 Jul; 33(4):e13502. PubMed ID: 32362061
[TBL] [Abstract][Full Text] [Related]
16. Pityriasis rosea Gibert type rash in an asymptomatic patient that tested positive for COVID-19.
Martín Enguix D; Salazar Nievas MDC; Martín Romero DT
Med Clin (Barc); 2020 Sep; 155(6):273. PubMed ID: 32654832
[No Abstract] [Full Text] [Related]
17. Smell and taste dysfunction in patients with COVID-19.
Xydakis MS; Dehgani-Mobaraki P; Holbrook EH; Geisthoff UW; Bauer C; Hautefort C; Herman P; Manley GT; Lyon DM; Hopkins C
Lancet Infect Dis; 2020 Sep; 20(9):1015-1016. PubMed ID: 32304629
[No Abstract] [Full Text] [Related]
18. Chilblain-like lesions during the COVID-19 pandemic: should we really worry?
Piccolo V; Neri I; Manunza F; Mazzatenta C; Bassi A
Int J Dermatol; 2020 Aug; 59(8):1026-1027. PubMed ID: 32496583
[No Abstract] [Full Text] [Related]
19. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.
Balasubramanian S; Nagendran TM; Ramachandran B; Ramanan AV
Indian Pediatr; 2020 Jul; 57(7):681-683. PubMed ID: 32393681
[No Abstract] [Full Text] [Related]
20. Cutaneous manifestation of COVID-19 reporting from Middle-Eastern countries: A point of view!
Abdelmaksoud A; Shakshouk H; Goldust M; Dursun R; Temiz SA; Vestita M
Int J Dermatol; 2020 Dec; 59(12):1547-1548. PubMed ID: 33099771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
